Hypothesis

Age-associated shifts in the gut microbiome increase circulating microbial metabolites that directly prime the complement alternative pathway in the bloodstream, leading to systemic C3 activation and subsequent deposition in the retina. This mechanistic link explains why systemic complement markers correlate with AMD stage and why gut-targeted interventions ameliorate retinal pathology.

Mechanistic Rationale

1. Microbial metabolite surge – Aging dysbiosis elevates production of lipopolysaccharide (LPS), trimethylamine N‑oxide (TMAO), and succinate. These molecules are known to bind pattern‑recognition receptors (TLR4, SUCNR1) on hepatic Kupffer cells and circulating monocytes, stimulating transcription of complement genes (C3, factor B, factor D) via NF‑κB and HIF‑1α pathways.
2. Alternative pathway amplification – LPS‑induced hepatic release of C3 and factor B raises baseline plasma C3 levels. Simultaneously, succinate‑activated SUCNR1 on neutrophils increases oxidative burst, generating properdin‑stabilizing conditions that favor spontaneous C3 hydrolysis (C3(H2O)) and formation of the C3 convertase (C3bBb). This creates a feed‑forward loop where even modest increases in C3b accelerate MAC assembly.
3. Retinal sequestration – The retina expresses low levels of complement regulators (CD55, CD59) relative to other tissues. Elevated plasma C3bBb and C5a can cross the compromised blood‑retinal barrier in aging, binding to exposed extracellular matrix epitopes on RPE basal lamina. Local C3a generation then triggers autocrine RPE inflammation and MAC deposition on photoreceptor outer segments.
4. Bidirectional feedback – Retinal injury releases DAMPs that further increase gut permeability via vagal‑mediated signaling, worsening dysbiosis and metabolite release, thereby closing the loop.

Testable Predictions

• Prediction 1: Germ‑free or antibiotic‑treated aged mice will show significantly lower plasma C3bBb activity and reduced retinal C3/MAC deposition compared with age‑matched conventionally housed controls, despite similar systemic inflammation markers.
• Prediction 2: Supplementation of aged mice with a succinate dehydrogenase inhibitor (to lower circulating succinate) will decrease hepatic C3 transcription (measured by qPCR) and attenuate drusen‑like deposits in vivo.
• Prediction 3: Fecal microbiota transplantation from aged AMD patients into young germ‑free mice will elevate plasma C3bBb levels and induce early retinal complement deposition, whereas transplantation from young healthy donors will not.
• Prediction 4: In human cohorts, plasma succinate and LPS‑binding protein (LBP) concentrations will positively correlate with serum C3a and retinal imaging biomarkers (drusen volume, MAC-positive areas) independent of age and CFH genotype.

Falsifiability

If any of the above interventions fail to alter retinal complement deposition despite confirmed changes in gut microbiota composition or metabolite levels, the hypothesis that microbiome‑driven systemic complement priming is a primary driver of retinal C3/MAC accumulation would be refuted. Conversely, consistent positive results across models would support a causal gut‑retina complement axis.

References

[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC11205777/ [2] https://www.retinalphysician.com/issues/2019/novemberdecember/inhibiting-complement-c3-in-dry-amd/ [3] https://pmc.ncbi.nlm.nih.gov/articles/PMC8195907/ [4] https://pmc.ncbi.nlm.nih.gov/articles/PMC12227035/ [5] https://pmc.ncbi.nlm.nih.gov/articles/PMC7463023/ [6] https://www.reviewofophthalmology.com/article/the-gut-microbiomes-impact-on-the-retina }